Conditions: Post-traumatic Stress Disorder
Keywords: post-traumatic stress disorder
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 10
Healthy volunteers: no

Brief summary:
In this study, we propose to employ a randomized, double-blind, placebo-controlled, outpatient clinical trial to test the efficacy, safety, and tolerability of a 160 mg and 40 mg challenge of the mGlu2/3 agonist pomaglumetad methionil relative to placebo in modulating fear-potentiated startle response and behavior in adults with post-traumatic stress disorder (PTSD) (N=30). Each participant will receive a single dose of the study drug (40 mg vs 160 mg vs placebo in a 1:1:1 ratio).

Detailed description:

Arms:
arm 1: Placebo, one dose arm 2: Pomaglumetad Methionil 40mg, one dose, one time arm 3: Pomaglumetad Methionil 160mg, one dose, one time

Interventions: intervention 1: Pomaglumetad Methionil 160mg intervention 2: Pomaglumetad Methionil 40mg intervention 3: Placebo
Intervention descriptions: intervention 1: Pomaglumetad Methionil 160mg, one dose, one time intervention 2: Pomaglumetad Methionil 40mg, one dose, one time intervention 3: Placebo, one dose, one time

Protocol document: